Võrdle meetodeid
Vaata valitud meetodeid kõrvuti; erinevad read on esile tõstetud.
| Sihtmolekuliga vahendatud ravimite farmakokineetika× | Füsioloogiapõhine farmakokineetika× | |
|---|---|---|
| Valdkond | Farmakoloogia | Farmakoloogia |
| Perekond | Process / pipeline | Process / pipeline |
| Tekkeaasta≠ | 2001 | 1997 |
| Looja≠ | Donald Mager and William Jusko | Ivan Nestorov |
| Tüüp≠ | nonlinear PK modeling | predictive modeling |
| Algallikas≠ | Mager, D. E., & Jusko, W. J. (2001). General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Journal of Pharmacokinetics and Pharmacodynamics, 28(6), 507-532. DOI ↗ | Nestorov, I. (1997). Sensitivity analysis of pharmacokinetic and pharmacodynamic systems. Journal of Pharmacokinetics and Biopharmaceutics, 25(4), 529-543. link ↗ |
| Rööpnimetused | TMDD, target-driven clearance | PBPK, PBPK modeling |
| Seotud | 3 | 3 |
| Kokkuvõte≠ | Target-mediated drug disposition (TMDD) is a mechanistic framework describing nonlinear pharmacokinetics arising from drug binding to a target receptor or protein. Developed by Mager and Jusko in 2001, TMDD explains saturable clearance, dose-dependent half-lives, and time-dependent changes in plasma concentrations observed with protein therapeutics and some small-molecule drugs. | PBPK is a mechanistic modeling framework that uses physiological parameters, tissue properties, and drug-specific attributes to predict drug concentration time profiles in the body. Developed rigorously in the 1990s by researchers including Nestorov, PBPK integrates anatomy, biochemistry, and kinetics to enable rational drug development, bridging in vitro data to clinical outcomes. |
| ScholarGateAndmestik ↗ |
|
|